Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIRVANA-1
2023-504166-37-00Phase 2Authorised
- Sponsor
- Arcagy-Gineco
- Start
- Feb 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of niraparib, bevacizumab, paclitaxel and carboplatin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Arcagy-Gineco. Primary endpoint: Progression-Free Survival. Planned start Feb 2022; status: authorised.
02
Drugs
niraparibbevacizumabpaclitaxelcarboplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2023-504166-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504166-37-00.